With complete remission success rates of up to 85% in blood cancer patients, chimeric antigen receptor T-cell (CAR-T) therapies have transformed cancer care since 2017, when Novartis AG’s Kymriah (tisagenlecleucel) became the first CAR-T to secure authorization from the US Food and Drug Administration.
Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved
Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.
